We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Blood Test Rules Out Future Dementia Risk

By LabMedica International staff writers
Posted on 07 Apr 2025

Previous studies have suggested that specific biomarkers, such as tau217, Neurofilament Light (NfL), and Glial Fibrillary Acidic Protein (GFAP), may be valuable for early dementia diagnosis. More...

However, most of these studies have involved individuals who sought medical care due to cognitive symptoms, such as memory difficulties. A larger, community-based study was needed to assess the predictive power of these biomarkers in the general population. Now, a new study published in Nature Medicine has explored the potential of these biomarkers to predict dementia, including Alzheimer's disease, up to ten years before an official diagnosis in cognitively healthy older adults living in the community.

This study, led by researchers at Karolinska Institutet (Stockholm, Sweden) and their collaborators, analyzed blood biomarkers in over 2,100 adults aged 60 and above, who were monitored over a period to track the development of dementia. Ten years later, 17% of participants had been diagnosed with dementia. The biomarkers tested in this study were found to be up to 83% accurate. However, the researchers observed that these biomarkers had low positive predictive values, meaning that elevated levels of the biomarkers alone could not reliably predict who would develop dementia in the next decade. As a result, the researchers recommend against using these biomarkers as widespread screening tools in the general population at this time. The study also suggested that combining the three most significant biomarkers—p-tau217 with NfL or GFAP—could enhance predictive accuracy.

“Our findings imply that if an individual has low levels of these biomarkers, their risk of developing dementia over the next decade is minimal," said Davide Vetrano, associate professor at the same department and the study's senior author. "This information could offer reassurance to individuals worried about their cognitive health, as it potentially rules out the future development of dementia. These biomarkers are promising, but they are currently not suitable as standalone screening tests to identify dementia risk in the general population.”


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.